DMP: Dermapharm Holding SE - Summary | Jitta

Dermapharm Holding SE

DEU:DMP

Price
€48.70
Loss Chance
47.5%
5.32JITTA SCORE
55.98%Over Jitta Line
Jitta Ranking
205 / 548
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (63)
Recent Business Performance (62)
Financial Strength (72)
Return to Shareholders (55)
Competitive Advantage (55)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Interest Coverage RatioGood
Revenue and EarningEarning decline from 2022-2025
Operating MarginInconsistent
SG&A to SalesIncreasing Every Year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.32
55.98%
4.52
82.89%
4.17
65.16%
Pharmaceuticals
3.43
100.00%
2.52
100.00%
3.43
33.86%
COMPANY DESCRIPTION
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.